Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refracto...
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Background
This phase I trial evaluated the safety and tolerability of milciclib, an inhibitor of multiple cyclin-dependent kinases and tropomycin receptor kinase A, in combination with gemcitabine in patients with refractory solid tumors.
Design
Sixteen patients were enrolled and treated with milciclib at three dose levels (45 mg/m
2
Alternative Titles
Full title
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1900488877
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1900488877
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s00280-017-3303-z
